C
Craif
Biotech & Life Sciences · Tokyo, Japan · Founded 2018
Molecular diagnostics company specializing in miRNA-based early cancer detection platform MoreLess
Craif Inc. is a molecular diagnostics company focused on developing innovative solutions for early cancer detection using miRNA-based technology. Founded in May 2018 by Ryuichi Onose and Yasui Takao, the company operates in the life sciences sector, serving healthcare providers, medical researchers, and diagnostic laboratories. Craif's core product is a miRNA-based platform designed to identify cancer at its earliest stages, thereby improving patient outcomes and reducing healthcare costs. The company generates revenue through the sale of diagnostic tests and partnerships with healthcare institutions and research organizations. Craif was selected for the 2024 Medtech Innovator Accelerator Cohort, highlighting its potential and innovation in the medical technology field.
Keywords: miRNA, early cancer detection, molecular diagnostics, healthcare, life sciences, innovation, Medtech, diagnostic tests, biotechnology, medical research.
Talent graph
Craif's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Craif's cap table
Sourced from Dealroom's funding history.
Global footprint
Where Craif has talent and traffic
team presence
Market sentiment
What the market is saying about Craif
An AI-synthesized read of the highest-engagement posts about Craif on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Craif on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.